4,040 Shares in Edwards Lifesciences Co. (NYSE:EW) Bought by Accent Capital Management LLC

Accent Capital Management LLC acquired a new stake in shares of Edwards Lifesciences Co. (NYSE:EWFree Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 4,040 shares of the medical research company’s stock, valued at approximately $308,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in EW. Cove Private Wealth LLC acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $974,000. Vanguard Group Inc. boosted its stake in shares of Edwards Lifesciences by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 52,363,400 shares of the medical research company’s stock valued at $3,992,709,000 after purchasing an additional 729,984 shares during the period. Wahed Invest LLC lifted its stake in Edwards Lifesciences by 6.5% in the fourth quarter. Wahed Invest LLC now owns 10,105 shares of the medical research company’s stock worth $771,000 after acquiring an additional 618 shares during the last quarter. Willner & Heller LLC purchased a new position in Edwards Lifesciences in the fourth quarter worth approximately $430,000. Finally, Greenwood Capital Associates LLC raised its holdings in Edwards Lifesciences by 1.7% during the fourth quarter. Greenwood Capital Associates LLC now owns 91,853 shares of the medical research company’s stock worth $7,004,000 after purchasing an additional 1,563 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Performance

EW traded down $0.42 during trading hours on Monday, hitting $86.87. 2,093,527 shares of the stock were exchanged, compared to its average volume of 3,387,409. The stock has a 50-day simple moving average of $87.65 and a 200-day simple moving average of $84.07. Edwards Lifesciences Co. has a 12 month low of $60.57 and a 12 month high of $96.12. The stock has a market cap of $52.35 billion, a price-to-earnings ratio of 37.44, a price-to-earnings-growth ratio of 3.19 and a beta of 1.11. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67.

Edwards Lifesciences (NYSE:EWGet Free Report) last announced its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The firm had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.58 billion. Analysts anticipate that Edwards Lifesciences Co. will post 2.77 earnings per share for the current year.

Insiders Place Their Bets

In other news, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $94.89, for a total transaction of $688,426.95. Following the transaction, the chief financial officer now directly owns 19,074 shares of the company’s stock, valued at $1,809,931.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $94.89, for a total transaction of $688,426.95. Following the completion of the transaction, the chief financial officer now owns 19,074 shares of the company’s stock, valued at $1,809,931.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Bernard J. Zovighian bought 580 shares of the firm’s stock in a transaction that occurred on Monday, May 6th. The shares were purchased at an average cost of $85.74 per share, with a total value of $49,729.20. Following the purchase, the chief executive officer now directly owns 3,268 shares of the company’s stock, valued at $280,198.32. The disclosure for this purchase can be found here. Insiders have sold 127,104 shares of company stock valued at $11,267,464 over the last three months. Company insiders own 1.27% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on EW. OTR Global raised shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a report on Tuesday, March 26th. Wells Fargo & Company boosted their price objective on shares of Edwards Lifesciences from $94.00 to $99.00 and gave the stock an “overweight” rating in a research report on Friday, April 26th. Evercore ISI cut their target price on shares of Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating for the company in a research note on Friday, April 26th. Citigroup raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and upped their price objective for the company from $98.00 to $105.00 in a research note on Wednesday, May 22nd. Finally, Royal Bank of Canada increased their target price on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the stock an “outperform” rating in a research report on Monday, April 15th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and fifteen have given a buy rating to the company. According to MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average price target of $95.06.

Check Out Our Latest Analysis on Edwards Lifesciences

About Edwards Lifesciences

(Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Read More

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.